Neutrophil activation marker CD15+ as a prognostic factor of ocular surface damage in type 2 diabetics


  • T. M. Zhmud Pirogov Vinnytsia National Medical University
  • G.I. Drozhzhyna SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"
  • L. M. Velychko SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"



cornea, ocular surface, neutrophil activation marker CD15 , type 2 diabetes, prognosis


Purpose: To evaluate the prognostic value of the neutrophil activation marker CD15+ in ocular surface damage in type 2 diabetics.

Material and Methods: This study was conducted from January 2021 to January 2021 at the Pirogov Vinnytsia Regional Clinical Hospital, the clinical site of the Medical University. A total of 60 type 2 diabetics (120 eyes) were enrolled, with an average age of 62.1 ± 5.24 years.

Results: The prognostic value of the percentage expression of CD15+ in ocular surface damage in type 2 diabetics was for the first time evaluated. A rather high sensitivity of the percentage expression of CD15 (88.3%) allows using it as a parameter for screening for the presence of ocular surface damage in type 2 diabetics. Type 2 diabetics with a percentage of >27% of CD15+ cells had 10.52 times increased odds of ocular surface damage (95%CI, 4.34–25.50; p < 0.0001), and this value of the percentage of CD15+ cells can be used for the purpose of screening for ocular surface damage with a sensitivity of 88.3% (95% СІ, 77.8-94.2) and specificity of 63.3% (95% СІ, 50.7-74.4).

Author Biography

G.I. Drozhzhyna, SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

доктор медичних наук, професор, завідувач відділу патології рогівки ДУ «Інституту очних хвороб та тканинної терапії ім. В.П. Філатова НАМН України».


Shih K, Lam KL, Tong L. A systematic review on the impact of diabetes mellitus on the ocular surface. Nutr Diabetes. 2017 Mar 20;7(3):e251.

Lin X, Xu B, Zheng Y, Coursey TG, Zhao Y, Li J, et al. Meibomian Gland Dysfunction in Type 2 Diabetic Patients. J Ophthalmol. 2017;2017:3047867.

Szlasa W, Wilk K, Knecht-Gurwin K, Gurwin A, Froń A, Sauer N, et al. Prognostic and Therapeutic Role of CD15 and CD15s in Cancer. Cancers (Basel). 2022 Apr 28;14(9):2203.

Nakayama F, Nishihara S, Iwasaki H, Kudo T, Okubo R, Kaneko M, et al. CD15 expression in mature granulocytes is determined by alpha 1,3-fucosyltransferase IX, but in promyelocytes and monocytes by alpha 1,3-fucosyltransferase IV. J Biol Chem. 2001; 276(19):16100-6.

Gadhoum SZ, Sackstein R. CD15 expression in human myeloid cell differentiation is regulated by sialidase activity. Nat Chem Biol. 2008;4(12):751-7.

Oh EJ, Bychkov A, Cho H, Kim TM, Bae JS, Lim DJ, Jung CK. Prognostic Implications of CD10 and CD15 Expression in Papillary Thyroid Carcinoma. Cancers (Basel). 2020;12(6):1413.

O'Rourke M, Fearon U, Sweeney CM, Basdeo SA, Fletcher JM, Murphy CC, Canavan M. The pathogenic role of dendritic cells in non-infectious anterior uveitis. Exp Eye Res. 2018 Aug:173:121-8.

Mun Y, Hwang JS, Shin YJ. Role of Neutrophils on the Ocular Surface. Int J Mol Sci. 2021; 22(19): 10386.

Lahoz-Beneytez J, Elemans M, Zhang Y, et al. Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives. Blood. 2016;127(26):3431-8.

Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012 Jan;130(1):90-100.

Yu Y, Sun B. Autophagy-mediated regulation of neutrophils and clinical applications. Burns Trauma. 2020 Jan 16:8:tkz001.

Gorbet M, Postnikoff C, Williams S. The Noninflammatory Phenotype of Neutrophils From the Closed-Eye Environment: A Flow Cytometry Analysis of Receptor Expression. Invest Ophthalmol Vis Sci. 2015;56(8):4582-4591.

Nelson JD, Wright JC. Conjunctival Goblet Cell Densities in Ocular Surface Disease. Arch Ophthalmol. 1984;102(7):1049-51.

Zhmud TM, Velychko LM, Drozhzhyna GI, Bogdanova OV. Percentage expression of neutrophil activation marker in the peripheral blood of patients with dry eye disease plus type 2 diabetes. J Ophthalmol (Ukraine). 2022;1:24-29.

Zhmud T, Drozhzhyna G, Malachkova N. Evaluation and comparison of subjective and objective anterior ocular surface damage in patients with type 2 diabetes mellitus and dry eye disease. Graefes Arch Clin Exp Ophthalmol. 2023 Feb;261(2):447-52.

Zhmud TM, Drozhzhyna GI, Demchuk AV. Cytological features of the bulbar conjunctiva in patients with type 2 diabetes mellitus. J Ophthalmol (Ukraine). 2022;1:84-8.

Sergeant ESG, 2018. Epitools Epidemiological Calculators. Ausvet. Available at:

Rolando M, Barabino S, Giannaccare G, Aragona P. Dealing with the Persistent Pathogenic Issues of Dry Eye Disease: The Importance of External and Internal Stimuli and Tissue Responses. J Clin Med. 2023 Mar 13;12(6):2205.

Postnikoff CK, Huisingh C, McGwin G, Nichols KK. Leukocyte Distribution in the Open Eye Tears of Normal and Dry Eye Subjects. Curr Eye Res. 2018 Oct;43(10):1253-9. 2018;43(10):1253-9.

Sambursky R, Davitt WF, Latkany R, et al. Sensitivity and Specificity of a Point-of-Care Matrix Metalloproteinase 9 Immunoassay for Diagnosing Inflammation Related to Dry Eye. JAMA Ophthalmol. 2013;131(1):24-28.



How to Cite

Zhmud TM, Drozhzhyna G, Velychko LM. Neutrophil activation marker CD15+ as a prognostic factor of ocular surface damage in type 2 diabetics. J.ophthalmol. (Ukraine) [Internet]. 2024 Feb. 29 [cited 2024 Apr. 22];(1):15-9. Available from:



Clinical Ophthalmology